A Phase 3, Multicenter, Randomized, Double-blind, Active Comparatorcontrolled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX¿23 Six Months Later in Immunocompetent Adults Between 18 and 49 Y

Project: Other project

Project Details

StatusFinished
Effective start/end date7/1/18 → 6/30/23

Funding

  • Merck Sharp & Dohme Corporation: $44,770.32